Follow The Filings

ABT Abbott Laboratories

Health Care, filed as ABBOTT LABS (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 4 managers in 2026 Q2, sold by 5

  • 3 Owners
  • #52
  • Max 0.5%
  • Master 0.02%
  • $7M
  • 2 add 1 reduce

In 2026 Q3 David Katz and Kentucky Trust added to Abbott Laboratories, while Murphy Pohlad trimmed.

Who owns this now

Largest portfolio weights among holders, up to 0.5% (Murphy Pohlad, Murphy Pohlad Asset Management). Not free-float ownership.

  1. Murphy Pohlad Reduce 0.46%
  2. David Katz Add 0.43%
  3. Kentucky Trust Co. Add 0.25%

Who owns ABT

Sorted by value, long equity only, as of 2026 Q3.

History
David Katz, Matrix Asset Advisors 0.43%, was 0.35% Add +11.7% 52,805 $5.2M History
Murphy Pohlad, Murphy Pohlad Asset Management 0.46%, was 0.48% Reduce −12.1% 13,350 $1.3M History
Kentucky Trust Co., Kentucky Trust 0.25%, was 0.21% Add +5.2% 4,968 $491K History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ABT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ABT insider trades
  • $4.4M bought by 4 insiders
  • $47.5M sold by 7 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. John A. McCoy Jr. Vice President and Controller
    Sale
    $2,958 27 shares at $109.54 0.1% of stake
    Traded Sep 2 Filed Sep 3
    ↗
  2. Robert B Ford CEO
    Sale
    $46.2M 398,832 shares at $115.85 57% of stake
    Traded Aug 25 Filed Aug 27
    ↗
  3. Louis H. Morrone Executive Vice President
    Sale
    $643K 5,850 shares at $109.83 7.6% of stake
    Traded Aug 11 Filed Aug 13
    ↗
  4. John G Stratton Director
    Buy
    $174K 2,000 shares at $86.82 +9.4% to stake
    Traded May 7 Filed Jun 18
    ↗
  5. Daniel J Starks Director
    Buy
    $927K 10,000 shares at $92.65 +0.1% to stake
    Traded Apr 27 Filed Apr 28
    ↗
  6. Philip P Boudreau CFO
    Buy
    $201K 2,200 shares at $91.50 New stake
    Traded Apr 23 Filed Apr 27
    ↗
  7. Elizabeth C. Cushman EVP, Gc and Secretary
    Sale
    $30K 263 shares at $115.58 0.7% of stake
    Traded Mar 2 Filed Mar 3
    ↗
  8. Eric Shroff Senior Vice President
    Sale
    $82K 709 shares at $115.58 1.8% of stake
    Traded Mar 2 Filed Mar 3
    ↗
  9. Louis H. Morrone Executive Vice President
    Sale
    $132K 1,144 shares at $115.58 1.5% of stake
    Traded Mar 2 Filed Mar 3
    ↗
  10. Mary K Moreland Executive Vice President
    Sale
    $71K 613 shares at $115.58 0.6% of stake
    Traded Mar 2 Filed Mar 3
    ↗
  11. John A. McCoy Jr. Vice President and Controller
    Sale
    $68K 585 shares at $115.58 2.3% of stake
    Traded Mar 2 Filed Mar 3
    ↗
  12. Daniel Gesua Sive Salvadori EVP and Group President
    Sale
    $102K 885 shares at $115.58 0.6% of stake
    Traded Mar 2 Filed Mar 3
    ↗
  13. Daniel J Starks Director
    Buy
    $1.1M 10,000 shares at $108.73 +0.1% to stake
    Traded Feb 4 Filed Feb 6
    ↗
  14. Robert B Ford CEO
    Buy
    $2M 18,800 shares at $107.13 +9.5% to stake
    Traded Jan 23 Filed Jan 26
    ↗
  15. Eric Shroff Senior Vice President
    Sale
    $203K 1,586 shares at $128.02 5% of stake
    Traded Nov 25, 2025 Filed Nov 25, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 23 stock grants, 15 share withholdings for taxes, 3 other transactions, 2 option exercises, and 1 gift.

Congress

24 members of Congress traded ABT in the last three years: 26 buys and 36 sales. 25 members listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Sep 18 filed Oct 12
  2. Rick W. Allen R-GA-12Spouse Sell $15K–$50K Jul 14 filed Aug 18
  3. Richard McCormick R-GA-7 Sell $1K–$15K Jul 30 filed Aug 14
  4. Mike Kelly R-PA-16Spouse Sell $1K–$15K Jul 17 filed Aug 12
  5. Alan Armstrong R-OK Sell $15K–$50K Mar 27 filed Jul 21
  6. Rick Larsen D-WA-2 Sell $1K–$15K Jul 8 filed Jul 12

SEC filings

Recent issuer filings from EDGAR, 8 shown.

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 5.02,5.03,5.07,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $40.11B $41.95B $44.33B
Gross profit * $22.13B $23.24B $25.01B
Gross margin * 55.2% 55.4% 56.4%
Net income $5.72B $13.4B $6.52B
Net margin * 14.3% 31.9% 14.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $22.67B $23.66B $26B
Total non-current assets * $50.54B $57.76B $60.72B
Total assets $73.21B $81.41B $86.71B
Total current liabilities $13.84B $14.16B $16.5B
Total equity $38.6B $47.66B $52.13B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $7.26B $8.56B $9.57B
Cash from investing -$3.13B -$2.34B -$2.42B
Cash from financing -$7.09B -$5.4B -$6.31B
Net change in cash -$2.99B $0.72B $0.906B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.